FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4383896180> ?p ?o ?g. }

• W4383896180 endingPage "731.e1" @default.
• W4383896180 startingPage "725" @default.
• W4383896180 abstract "Background: Cardiovascular disease (CVD) is a leading cause of morbidity and mortality among adolescents and young adults (AYAs) diagnosed with cancer. The aim of this study was to assess the incidence and predictors of left ventricular systolic dysfunction (LVSD) and hypertension among AYAs receiving VEGF inhibition compared with non-AYAs. Methods: This retrospective analysis used data from the ASSURE trial (ClinicalTrials.gov identifier: NCT00326898 ), in which participants with nonmetastatic, high-risk, renal cell cancer were randomized to sunitinib, sorafenib, or placebo. The incidence of LVSD (left ventricular ejection fraction decrease >15%) and hypertension (blood pressure ≥140/90 mm Hg) were compared using nonparametric tests. Multivariable logistic regression examined the association between AYA status, LVSD, and hypertension while adjusting for clinical factors. Results: AYAs represented 7% (103/1,572) of the population. Over a study treatment period of 54 weeks, the incidence of LVSD was not significantly different among AYAs (3%; 95% CI, 0.6%–8.3%) versus non-AYAs (2%; 95% CI, 1.2%–2.7%). The incidence of hypertension was significantly lower among AYAs (18%; 95% CI, 7.5%–33.5%) compared with non-AYAs (46%; 95% CI, 41.9%–50.4%) in the placebo arm. In the sunitinib and sorafenib groups, the incidence of hypertension for AYAs compared with non-AYAs was 29% (95% CI, 15.1%–47.5%) versus 47% (95% CI, 42.3%–51.7%), and 54% (95% CI, 33.9%–72.5%) versus 63% (95% CI, 58.6%–67.7%), respectively. AYA status (odds ratio, 0.48; 95% CI, 0.31–0.75) and female sex (odds ratio, 0.74; 95% CI, 0.59–0.92) were each associated with a lower risk of hypertension. Conclusions: LVSD and hypertension were prevalent among AYAs. CVD among AYAs is only partially explained by cancer therapy. Understanding CVD risk among AYA cancer survivors is important for promoting cardiovascular health in this growing population." @default.
• W4383896180 created "2023-07-12" @default.
• W4383896180 creator A5000869633 @default.
• W4383896180 creator A5016115956 @default.
• W4383896180 creator A5030616091 @default.
• W4383896180 creator A5036287306 @default.
• W4383896180 creator A5037443640 @default.
• W4383896180 creator A5039180386 @default.
• W4383896180 creator A5046123003 @default.
• W4383896180 creator A5056341385 @default.
• W4383896180 creator A5074000801 @default.
• W4383896180 creator A5086484380 @default.
• W4383896180 creator A5090879940 @default.
• W4383896180 date "2023-07-01" @default.
• W4383896180 modified "2023-10-17" @default.
• W4383896180 title "Cardiovascular Implications of Vascular Endothelial Growth Factor Inhibition Among Adolescents/Young Adults in ECOG-ACRIN E2805" @default.
• W4383896180 cites W1544142122 @default.
• W4383896180 cites W1880435494 @default.
• W4383896180 cites W1907991309 @default.
• W4383896180 cites W1965356337 @default.
• W4383896180 cites W1969206151 @default.
• W4383896180 cites W1985429138 @default.
• W4383896180 cites W2081932726 @default.
• W4383896180 cites W2098775844 @default.
• W4383896180 cites W2109227311 @default.
• W4383896180 cites W2116949558 @default.
• W4383896180 cites W2149259234 @default.
• W4383896180 cites W2149456801 @default.
• W4383896180 cites W2164487516 @default.
• W4383896180 cites W2170484522 @default.
• W4383896180 cites W2259143846 @default.
• W4383896180 cites W2293077587 @default.
• W4383896180 cites W2296515391 @default.
• W4383896180 cites W2298991506 @default.
• W4383896180 cites W2559298745 @default.
• W4383896180 cites W2563522215 @default.
• W4383896180 cites W2588815342 @default.
• W4383896180 cites W2791906702 @default.
• W4383896180 cites W2897838742 @default.
• W4383896180 cites W2968344727 @default.
• W4383896180 cites W2980119731 @default.
• W4383896180 cites W3003765125 @default.
• W4383896180 cites W3107606740 @default.
• W4383896180 cites W3213586312 @default.
• W4383896180 cites W4220949607 @default.
• W4383896180 cites W4221083501 @default.
• W4383896180 doi "https://doi.org/10.6004/jnccn.2023.7018" @default.
• W4383896180 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37433436" @default.
• W4383896180 hasPublicationYear "2023" @default.
• W4383896180 type Work @default.
• W4383896180 citedByCount "0" @default.
• W4383896180 crossrefType "journal-article" @default.
• W4383896180 hasAuthorship W4383896180A5000869633 @default.
• W4383896180 hasAuthorship W4383896180A5016115956 @default.
• W4383896180 hasAuthorship W4383896180A5030616091 @default.
• W4383896180 hasAuthorship W4383896180A5036287306 @default.
• W4383896180 hasAuthorship W4383896180A5037443640 @default.
• W4383896180 hasAuthorship W4383896180A5039180386 @default.
• W4383896180 hasAuthorship W4383896180A5046123003 @default.
• W4383896180 hasAuthorship W4383896180A5056341385 @default.
• W4383896180 hasAuthorship W4383896180A5074000801 @default.
• W4383896180 hasAuthorship W4383896180A5086484380 @default.
• W4383896180 hasAuthorship W4383896180A5090879940 @default.
• W4383896180 hasBestOaLocation W43838961801 @default.
• W4383896180 hasConcept C120665830 @default.
• W4383896180 hasConcept C121332964 @default.
• W4383896180 hasConcept C121608353 @default.
• W4383896180 hasConcept C126322002 @default.
• W4383896180 hasConcept C142724271 @default.
• W4383896180 hasConcept C156957248 @default.
• W4383896180 hasConcept C204787440 @default.
• W4383896180 hasConcept C205545832 @default.
• W4383896180 hasConcept C27081682 @default.
• W4383896180 hasConcept C2779490328 @default.
• W4383896180 hasConcept C2908647359 @default.
• W4383896180 hasConcept C61511704 @default.
• W4383896180 hasConcept C71924100 @default.
• W4383896180 hasConcept C84393581 @default.
• W4383896180 hasConcept C99454951 @default.
• W4383896180 hasConceptScore W4383896180C120665830 @default.
• W4383896180 hasConceptScore W4383896180C121332964 @default.
• W4383896180 hasConceptScore W4383896180C121608353 @default.
• W4383896180 hasConceptScore W4383896180C126322002 @default.
• W4383896180 hasConceptScore W4383896180C142724271 @default.
• W4383896180 hasConceptScore W4383896180C156957248 @default.
• W4383896180 hasConceptScore W4383896180C204787440 @default.
• W4383896180 hasConceptScore W4383896180C205545832 @default.
• W4383896180 hasConceptScore W4383896180C27081682 @default.
• W4383896180 hasConceptScore W4383896180C2779490328 @default.
• W4383896180 hasConceptScore W4383896180C2908647359 @default.
• W4383896180 hasConceptScore W4383896180C61511704 @default.
• W4383896180 hasConceptScore W4383896180C71924100 @default.
• W4383896180 hasConceptScore W4383896180C84393581 @default.
• W4383896180 hasConceptScore W4383896180C99454951 @default.
• W4383896180 hasIssue "7" @default.
• W4383896180 hasLocation W43838961801 @default.
• W4383896180 hasLocation W43838961802 @default.
• W4383896180 hasOpenAccess W4383896180 @default.

• next